Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about BeOne Medicines Ltd.
BeOne Medicines Ltd. News
BeOne Medicines Ltd. Quantitative Score

About BeOne Medicines Ltd.
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
BeOne Medicines Ltd. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
BeOne Medicines Ltd. Financials
Table Compare
Compare ONC metrics with: | |||
---|---|---|---|
Earnings & Growth | ONC | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ONC | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ONC | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ONC | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
BeOne Medicines Ltd. Income
BeOne Medicines Ltd. Balance Sheet
BeOne Medicines Ltd. Cash Flow
BeOne Medicines Ltd. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Sell |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
BeOne Medicines Ltd. Executives
Name | Role |
---|---|
Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder |
Mr. John V. Oyler | Co-Founder, Executive Chairman & Chief Executive Officer |
Mr. Aaron Rosenberg | Chief Financial Officer |
Dr. Xiaobin Wu Ph.D. | President, Chief Operating Officer & GM of China |
Mr. Wang Lai Ph.D. | Global Head of R&D |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | 1963 | 4.25M | |
Mr. John V. Oyler | Co-Founder, Executive Chairman & Chief Executive Officer | Male | 1968 | 2.84M |
Mr. Aaron Rosenberg | Chief Financial Officer | Male | 1977 | 1.93M |
Dr. Xiaobin Wu Ph.D. | President, Chief Operating Officer & GM of China | 1963 | 1.84M | |
Mr. Wang Lai Ph.D. | Global Head of R&D | Male | 1978 | 1.2M |
BeOne Medicines Ltd. Insider Trades
Date | 10 Jun |
Name | Ball Titus B. |
Role | Principal Accounting Officer |
Transaction | Acquired |
Type | A-Award |
Shares | 29601 |
Date | 11 Jun |
Name | Ball Titus B. |
Role | Principal Accounting Officer |
Transaction | Disposed |
Type | S-Sale |
Shares | 134 |
Date | 10 Jun |
Name | Lee Chan Henry |
Role | SVP, General Counsel |
Transaction | Acquired |
Type | A-Award |
Shares | 46878 |
Date | 10 Jun |
Name | Lee Chan Henry |
Role | SVP, General Counsel |
Transaction | Acquired |
Type | A-Award |
Shares | 88244 |
Date | 10 Jun |
Name | Rosenberg Aaron |
Role | Chief Financial Officer |
Transaction | Acquired |
Type | A-Award |
Shares | 63674 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
10 Jun | Ball Titus B. | Principal Accounting Officer | Acquired | A-Award | 29601 |
11 Jun | Ball Titus B. | Principal Accounting Officer | Disposed | S-Sale | 134 |
10 Jun | Lee Chan Henry | SVP, General Counsel | Acquired | A-Award | 46878 |
10 Jun | Lee Chan Henry | SVP, General Counsel | Acquired | A-Award | 88244 |
10 Jun | Rosenberg Aaron | Chief Financial Officer | Acquired | A-Award | 63674 |